Annals of oncology : official journal of the European Society for Medical Oncology
-
Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies. We carried out a phase I-II clinical trial with the combination of bevacizumab and continuous dose-intense temozolomide (TMZ) for patients with a recurrent HGG after first- or second-line treatment. ⋯ Treatment with bevacizumab and TMZ is feasible and well tolerated but did not improve PFS6 and median OS.